Originally published on Best Stocks Category: best stocks to buy nowOn Monday, October 3, Jazz Pharmaceuticals plc (NASDAQ: JAZZ) sold 45,185 shares of the company’s stock. With an average price of $134.93 per share, the transaction’s full value came to $6,096,812,05. The CEO ultimately purchased 374,028 shares of the business for a total of $50,467,598.04. On the Securities and Exchange Commission website, you can find a copy of the document that told about the sale. Deposit $100 and get a $110 to trade stocks>>>>>>>>>>Open Account On August 3, Jazz Pharmaceuticals (NASDAQ: JAZZ) announced its most recent earnings report. The specialized pharmaceutical company’s $3.62 earnings per share for the quarter significantly lagged analysts’ forecasts of $3.63. (0.01). The company’s sales for the quarter totaled $932.88 million, exceeding the $908.23 million expert consensus. Jazz Pharmaceuticals reported a 1.49% negative net margin and a 25.50% positive return on equity. This year, equity research analysts forecast 15.37 EPS from Jazz Pharmaceuticals plc.Brokerages have recently made comments about JAZZ. The Goldman Sachs Group raised their price target on shares of Jazz Pharmaceuticals from $148.00 to $170.00 in a research note released on Thursday, September 29, and rated the stock as “neutral.” In a research note released on August 4, Morgan Stanley raised their price objective on Jazz Pharmaceuticals from $174.00 to $187.00 and upgraded the company from “equal weight” to “overweight.” In a research note issued on Thursday, August 4, BMO Capital Markets maintained its “outperform” rating while increasing its target price on shares of Jazz Pharmaceuticals from $185.00 to $188.00. SVB Leerink raised their target price on shares of Jazz Pharmaceuticals from $200.00 to $210.00 and rated the stock with an “outperform” rating in a research note on Thursday, August 4. In a research note issued on Friday, August 5, HC Wainwright reduced their target price on Jazz Pharmaceuticals shares from $210.00 to $204.00.TEN research analysts have rated the company as a buy versus two who have rated it as a hold. Data from Bloomberg.com shows that the average rating for the company is “Moderate Buy,” and the average target price is $201.69. JAZZ shares fell $2.02 on Wednesday to settle at $136.39 on the NASDAQ. The total volume of shares exchanged for the company was 525,918, less than the typical 569,464 shares. The firm is well-capitalized with a market value of $8.52 billion, a price-to-earnings ratio of-160.86, a PEG ratio of 0.77, and a beta of 0.73. Jazz Pharmaceuticals plc has a 52-week high of $169.98 and a 52-week low of $117.64. The company’s 50-day moving average is $149.69, and its 200-day moving average is $153.18, respectively. The company’s quick, current, and debt-to-equity ratios are, respectively, 2.45, 3.67, and 1.87. Hedge funds and institutional investors now own varying percentages of a corporation:CIBC World Markets Inc. boosted its stake in Jazz Pharmaceuticals by 43.5% in the fourth quarter. CIBC World Markets Inc. now owns 23,622 shares of the specialty pharmaceutical company’s stock, valued at $3,009,000, after acquiring an additional 7,166 shares over the last quarter.Jazz Pharmaceuticals received a fresh investment from Millennium Management LLC in the fourth quarter for about $56,159,000.Loomis Sayles & Co. L.P. grew its stake in Jazz Pharmaceuticals by 3.4% in the fourth quarter. After acquiring an extra 6,119 shares over the weekend, Loomis Sayles & Co. L.P. now directly owns 188,351 shares of the specialty pharmaceutical company’s stock, valued at $23,995,000.Samlyn Capital LLC grew its stake in Jazz Pharmaceuticals by 25.3% in the fourth quarter.There are currently 132,383 shares outstanding for the specialty pharmaceutical company, a rise of 83,533,000 from two months ago. And finally, during the fourth quarter, Belpointe Asset Management LLC purchased a new position in Jazz Pharmaceuticals for about $1,031,000. Institutional and hedge fund investors hold 92.79% of the stock in total. Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, creates, and markets pharmaceutical treatments for various unmet medical needs in the U.S., Europe, and other nations. The company has a portfolio of pharmaceuticals and product prospects, focusing on neurology, such as sleep medicine and movement disorders, and cancer, such as hematologic and solid malignancies.